Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Pharmacokinetics and Pharmacodynamics of LY2599666, a PEG-Linked Antigen Binding Fragment that Targets Soluble Monomer Amyloid-β.

Li L, Zhen EY, Decker RL, Willis BA, Waters D, Liu P, Hake AM, Demattos RB, Ayan-Oshodi M.

J Alzheimers Dis. 2019;68(1):137-144. doi: 10.3233/JAD-180925.

PMID:
30741684
2.

Genome-wide RNAseq study of the molecular mechanisms underlying microglia activation in response to pathological tau perturbation in the rTg4510 tau transgenic animal model.

Wang H, Li Y, Ryder JW, Hole JT, Ebert PJ, Airey DC, Qian HR, Logsdon B, Fisher A, Ahmed Z, Murray TK, Cavallini A, Bose S, Eastwood BJ, Collier DA, Dage JL, Miller BB, Merchant KM, O'Neill MJ, Demattos RB.

Mol Neurodegener. 2018 Dec 17;13(1):65. doi: 10.1186/s13024-018-0296-y.

3.

Central pharmacodynamic activity of solanezumab in mild Alzheimer's disease dementia.

Willis BA, Sundell K, Lachno DR, Ferguson-Sells LR, Case MG, Holdridge K, DeMattos RB, Raskin J, Siemers ER, Dean RA.

Alzheimers Dement (N Y). 2018 Nov 9;4:652-660. doi: 10.1016/j.trci.2018.10.001. eCollection 2018.

4.

TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques.

Wang Y, Ulland TK, Ulrich JD, Song W, Tzaferis JA, Hole JT, Yuan P, Mahan TE, Shi Y, Gilfillan S, Cella M, Grutzendler J, DeMattos RB, Cirrito JR, Holtzman DM, Colonna M.

J Exp Med. 2016 May 2;213(5):667-75. doi: 10.1084/jem.20151948. Epub 2016 Apr 18.

5.

β-site amyloid precursor protein-cleaving enzyme 1(BACE1) inhibitor treatment induces Aβ5-X peptides through alternative amyloid precursor protein cleavage.

Portelius E, Dean RA, Andreasson U, Mattsson N, Westerlund A, Olsson M, Demattos RB, Racke MM, Zetterberg H, May PC, Blennow K.

Alzheimers Res Ther. 2014 Nov 17;6(5-8):75. doi: 10.1186/s13195-014-0075-0. eCollection 2014.

6.

Anti-Aβ antibody target engagement: commentary regarding Watt et al. Acta Neuropathol 127:803-810 (2014).

Siemers E, Dean RA, DeMattos RB, Hutton ML, Blennow K, Shaw LM, Holtzman DM.

Acta Neuropathol. 2014 Oct;128(4):609-10. doi: 10.1007/s00401-014-1332-9. Epub 2014 Aug 14. No abstract available.

PMID:
25120192
7.

Validation of assays for measurement of amyloid-β peptides in cerebrospinal fluid and plasma specimens from patients with Alzheimer's disease treated with solanezumab.

Lachno DR, Evert BA, Vanderstichele H, Robertson M, Demattos RB, Konrad RJ, Talbot JA, Racke MM, Dean RA.

J Alzheimers Dis. 2013;34(4):897-910. doi: 10.3233/JAD-122317.

PMID:
23302661
8.

A plaque-specific antibody clears existing β-amyloid plaques in Alzheimer's disease mice.

Demattos RB, Lu J, Tang Y, Racke MM, Delong CA, Tzaferis JA, Hole JT, Forster BM, McDonnell PC, Liu F, Kinley RD, Jordan WH, Hutton ML.

Neuron. 2012 Dec 6;76(5):908-20. doi: 10.1016/j.neuron.2012.10.029.

9.

Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Aβ clearance in a mouse model of β-amyloidosis.

Castellano JM, Deane R, Gottesdiener AJ, Verghese PB, Stewart FR, West T, Paoletti AC, Kasper TR, DeMattos RB, Zlokovic BV, Holtzman DM.

Proc Natl Acad Sci U S A. 2012 Sep 18;109(38):15502-7. Epub 2012 Aug 27.

10.

Safety and biomarker effects of solanezumab in patients with Alzheimer's disease.

Farlow M, Arnold SE, van Dyck CH, Aisen PS, Snider BJ, Porsteinsson AP, Friedrich S, Dean RA, Gonzales C, Sethuraman G, DeMattos RB, Mohs R, Paul SM, Siemers ER.

Alzheimers Dement. 2012 Jul;8(4):261-71. doi: 10.1016/j.jalz.2011.09.224. Epub 2012 Jun 5.

PMID:
22672770
11.

Midlife blood pressure, plasma β-amyloid, and the risk for Alzheimer disease: the Honolulu Asia Aging Study.

Shah NS, Vidal JS, Masaki K, Petrovitch H, Ross GW, Tilley C, DeMattos RB, Tracy RP, White LR, Launer LJ.

Hypertension. 2012 Apr;59(4):780-6. doi: 10.1161/HYPERTENSIONAHA.111.178962. Epub 2012 Mar 5.

12.

Human apoE isoforms differentially regulate brain amyloid-β peptide clearance.

Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, Patterson BW, Fagan AM, Morris JC, Mawuenyega KG, Cruchaga C, Goate AM, Bales KR, Paul SM, Bateman RJ, Holtzman DM.

Sci Transl Med. 2011 Jun 29;3(89):89ra57. doi: 10.1126/scitranslmed.3002156.

13.

Validation of ELISA methods for quantification of total tau and phosporylated-tau181 in human cerebrospinal fluid with measurement in specimens from two Alzheimer's disease studies.

Lachno DR, Romeo MJ, Siemers ER, Vanderstichele H, Coart E, Konrad RJ, Zajac JJ, Talbot JA, Jensen HF, Sethuraman G, Demattos RB, May PC, Dean RA.

J Alzheimers Dis. 2011;26(3):531-41. doi: 10.3233/JAD-2011-110296.

PMID:
21694458
14.

Animal models for neural diseases.

Jay GW, Demattos RB, Weinstein EJ, Philbert MA, Pardo ID, Brown TP.

Toxicol Pathol. 2011 Jan;39(1):167-9. doi: 10.1177/0192623310389478. Epub 2010 Nov 30.

15.

Role of biochemical Alzheimer's disease biomarkers as end points in clinical trials.

Siemers E, DeMattos RB, May PC, Dean RA.

Biomark Med. 2010 Feb;4(1):81-9. Review.

PMID:
20387304
16.

Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease.

Siemers ER, Friedrich S, Dean RA, Gonzales CR, Farlow MR, Paul SM, Demattos RB.

Clin Neuropharmacol. 2010 Mar-Apr;33(2):67-73. doi: 10.1097/WNF.0b013e3181cb577a.

PMID:
20375655
17.

A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system.

Bateman RJ, Siemers ER, Mawuenyega KG, Wen G, Browning KR, Sigurdson WC, Yarasheski KE, Friedrich SW, Demattos RB, May PC, Paul SM, Holtzman DM.

Ann Neurol. 2009 Jul;66(1):48-54. doi: 10.1002/ana.21623.

18.

ABCG1 influences the brain cholesterol biosynthetic pathway but does not affect amyloid precursor protein or apolipoprotein E metabolism in vivo.

Burgess BL, Parkinson PF, Racke MM, Hirsch-Reinshagen V, Fan J, Wong C, Stukas S, Theroux L, Chan JY, Donkin J, Wilkinson A, Balik D, Christie B, Poirier J, Lütjohann D, Demattos RB, Wellington CL.

J Lipid Res. 2008 Jun;49(6):1254-67. doi: 10.1194/jlr.M700481-JLR200. Epub 2008 Feb 26.

19.

Liver X receptor-mediated gene regulation and cholesterol homeostasis in brain: relevance to Alzheimer's disease therapeutics.

Cao G, Bales KR, DeMattos RB, Paul SM.

Curr Alzheimer Res. 2007 Apr;4(2):179-84. Review.

PMID:
17430244
20.

The cholesterol transporter ABCG1 modulates the subcellular distribution and proteolytic processing of beta-amyloid precursor protein.

Tansley GH, Burgess BL, Bryan MT, Su Y, Hirsch-Reinshagen V, Pearce J, Chan JY, Wilkinson A, Evans J, Naus KE, McIsaac S, Bromley K, Song W, Yang HC, Wang N, DeMattos RB, Wellington CL.

J Lipid Res. 2007 May;48(5):1022-34. Epub 2007 Feb 10.

21.

The low density lipoprotein receptor regulates the level of central nervous system human and murine apolipoprotein E but does not modify amyloid plaque pathology in PDAPP mice.

Fryer JD, Demattos RB, McCormick LM, O'Dell MA, Spinner ML, Bales KR, Paul SM, Sullivan PM, Parsadanian M, Bu G, Holtzman DM.

J Biol Chem. 2005 Jul 8;280(27):25754-9. Epub 2005 May 11.

22.

Production and characterization of astrocyte-derived human apolipoprotein E isoforms from immortalized astrocytes and their interactions with amyloid-beta.

Morikawa M, Fryer JD, Sullivan PM, Christopher EA, Wahrle SE, DeMattos RB, O'Dell MA, Fagan AM, Lashuel HA, Walz T, Asai K, Holtzman DM.

Neurobiol Dis. 2005 Jun-Jul;19(1-2):66-76.

PMID:
15837562
23.

Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta.

Racke MM, Boone LI, Hepburn DL, Parsadainian M, Bryan MT, Ness DK, Piroozi KS, Jordan WH, Brown DD, Hoffman WP, Holtzman DM, Bales KR, Gitter BD, May PC, Paul SM, DeMattos RB.

J Neurosci. 2005 Jan 19;25(3):629-36.

24.

In situ AFM studies of astrocyte-secreted apolipoprotein E- and J-containing lipoproteins.

Legleiter J, DeMattos RB, Holtzman DM, Kowalewski T.

J Colloid Interface Sci. 2004 Oct 1;278(1):96-106.

PMID:
15313642
25.

Alzheimer A beta vaccination of rhesus monkeys (Macaca mulatta).

Gandy S, DeMattos RB, Lemere CA, Heppner FL, Leverone J, Aguzzi A, Ershler WB, Dai J, Fraser P, Hyslop PS, Holtzman DM, Walker LC, Keller ET.

Alzheimer Dis Assoc Disord. 2004 Jan-Mar;18(1):44-6.

PMID:
15195463
26.
27.

Alzheimer's Abeta vaccination of rhesus monkeys (Macaca mulatta).

Gandy S, DeMattos RB, Lemere CA, Heppner FL, Leverone J, Aguzzi A, Ershler WB, Dai J, Fraser P, St George Hyslop P, Holtzman DM, Walker LC, Keller ET.

Mech Ageing Dev. 2004 Feb;125(2):149-51.

PMID:
15037022
28.

Apolipoprotein E, amyloid, and Alzheimer disease.

Bales KR, Dodart JC, DeMattos RB, Holtzman DM, Paul SM.

Mol Interv. 2002 Oct;2(6):363-75, 339. Review.

PMID:
14993413
29.

ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo.

DeMattos RB, Cirrito JR, Parsadanian M, May PC, O'Dell MA, Taylor JW, Harmony JA, Aronow BJ, Bales KR, Paul SM, Holtzman DM.

Neuron. 2004 Jan 22;41(2):193-202.

30.

A liver X receptor and retinoid X receptor heterodimer mediates apolipoprotein E expression, secretion and cholesterol homeostasis in astrocytes.

Liang Y, Lin S, Beyer TP, Zhang Y, Wu X, Bales KR, DeMattos RB, May PC, Li SD, Jiang XC, Eacho PI, Cao G, Paul SM.

J Neurochem. 2004 Feb;88(3):623-34.

31.

Effect of different anti-Abeta antibodies on Abeta fibrillogenesis as assessed by atomic force microscopy.

Legleiter J, Czilli DL, Gitter B, DeMattos RB, Holtzman DM, Kowalewski T.

J Mol Biol. 2004 Jan 23;335(4):997-1006.

PMID:
14698294
32.

In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life.

Cirrito JR, May PC, O'Dell MA, Taylor JW, Parsadanian M, Cramer JW, Audia JE, Nissen JS, Bales KR, Paul SM, DeMattos RB, Holtzman DM.

J Neurosci. 2003 Oct 1;23(26):8844-53.

33.

Evidence for peripheral clearance of cerebral Abeta protein following chronic, active Abeta immunization in PSAPP mice.

Lemere CA, Spooner ET, LaFrancois J, Malester B, Mori C, Leverone JF, Matsuoka Y, Taylor JW, DeMattos RB, Holtzman DM, Clements JD, Selkoe DJ, Duff KE.

Neurobiol Dis. 2003 Oct;14(1):10-8.

PMID:
13678662
34.

Apolipoprotein E markedly facilitates age-dependent cerebral amyloid angiopathy and spontaneous hemorrhage in amyloid precursor protein transgenic mice.

Fryer JD, Taylor JW, DeMattos RB, Bales KR, Paul SM, Parsadanian M, Holtzman DM.

J Neurosci. 2003 Aug 27;23(21):7889-96.

35.

Abeta immunization and anti-Abeta antibodies: potential therapies for the prevention and treatment of Alzheimer's disease.

Holtzman DM, Bales KR, Paul SM, DeMattos RB.

Adv Drug Deliv Rev. 2002 Dec 7;54(12):1603-13. Review.

PMID:
12453677
36.

Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease.

DeMattos RB, O'dell MA, Parsadanian M, Taylor JW, Harmony JA, Bales KR, Paul SM, Aronow BJ, Holtzman DM.

Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10843-8. Epub 2002 Jul 26.

37.

Plaque-associated disruption of CSF and plasma amyloid-beta (Abeta) equilibrium in a mouse model of Alzheimer's disease.

DeMattos RB, Bales KR, Parsadanian M, O'Dell MA, Foss EM, Paul SM, Holtzman DM.

J Neurochem. 2002 Apr;81(2):229-36.

38.

Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model.

Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, DeLong CA, Wu S, Wu X, Holtzman DM, Paul SM.

Nat Neurosci. 2002 May;5(5):452-7.

PMID:
11941374
39.

Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease.

DeMattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM.

Science. 2002 Mar 22;295(5563):2264-7.

40.

Purification and characterization of astrocyte-secreted apolipoprotein E and J-containing lipoproteins from wild-type and human apoE transgenic mice.

DeMattos RB, Brendza RP, Heuser JE, Kierson M, Cirrito JR, Fryer J, Sullivan PM, Fagan AM, Han X, Holtzman DM.

Neurochem Int. 2001 Nov-Dec;39(5-6):415-25.

PMID:
11578777
41.

Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease.

DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM.

Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8850-5. Epub 2001 Jul 3.

42.

Biochemical analysis of cell-derived apoE3 particles active in stimulating neurite outgrowth.

DeMattos RB, Rudel LL, Williams DL.

J Lipid Res. 2001 Jun;42(6):976-87.

43.

Clusterin contributes to caspase-3-independent brain injury following neonatal hypoxia-ischemia.

Han BH, DeMattos RB, Dugan LL, Kim-Han JS, Brendza RP, Fryer JD, Kierson M, Cirrito J, Quick K, Harmony JA, Aronow BJ, Holtzman DM.

Nat Med. 2001 Mar;7(3):338-43.

PMID:
11231633
46.
47.
48.

Lack of correlation between ACAT mRNA expression and cholesterol esterification in primary liver cells.

Rea TJ, DeMattos RB, Homan R, Newton RS, Pape ME.

Biochim Biophys Acta. 1996 Jan 5;1299(1):67-74.

PMID:
8555254
49.

Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-III expression: a potential physiologic basis for their mode of action.

Haubenwallner S, Essenburg AD, Barnett BC, Pape ME, DeMattos RB, Krause BR, Minton LL, Auerbach BJ, Newton RS, Leff T, et al.

J Lipid Res. 1995 Dec;36(12):2541-51.

50.

Tissue specific changes in acyl-CoA: cholesterol acyltransferase (ACAT) mRNA levels in rabbits.

Pape ME, Schultz PA, Rea TJ, DeMattos RB, Kieft K, Bisgaier CL, Newton RS, Krause BR.

J Lipid Res. 1995 Apr;36(4):823-38.

Supplemental Content

Loading ...
Support Center